GDF-3 Inhibitors
Chemical inhibitors of Growth Differentiation Factor 3 (GDF-3) act through various mechanisms to modulate the signaling pathways that GDF-3 utilizes in its biological role. Dorsomorphin and its analog LDN-193189, for instance, selectively target the BMP signaling pathway, a crucial route through which GDF-3 exerts its effects. These inhibitors function by directly impeding the activity of BMP type I receptors, thwarting the phosphorylation and subsequent activation of SMAD proteins, and thereby inhibiting the downstream signaling that is typically propagated by GDF-3. Another compound, SB-431542, operates by selectively inhibiting the activin receptor-like kinases (ALK) within the TGF-beta signaling pathway. Since GDF-3 is a member of the TGF-beta superfamily, the inhibition of these kinases by SB-431542 disrupts the signal transduction that GDF-3 would normally participate in.
Continuing the theme of signal inhibition, DMH1 and K02288 also serve as selective BMP receptor inhibitors, thus interfering with the BMP signaling cascade that GDF-3 engages with. Similarly, LDN-214117 impedes ALK2 and ALK3, which are receptors GDF-3 may interact with, thereby functionally reducing GDF-3 signaling. A 83-01 extends this inhibitory effect by targeting ALK5 and ALK7, along with TGF-beta type I receptors, further impeding the signaling capabilities of GDF-3. ML347, LDN-212854, and DMH2 also play roles in inhibiting BMP type I receptors such as ALK1, ALK2, ALK3, and ALK6, which are integral components of the pathways employed by GDF-3. ALK5 Inhibitor II specifically targets the TGF-beta type I receptor ALK5, integral to GDF-3 signaling pathways. Lastly, Alantolactone disrupts GDF-3 activity by inhibiting SMAD3 phosphorylation, a key event in the downstream signaling of the TGF-beta superfamily to which GDF-3 belongs.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsomorphin inhibits BMP signaling, which is a pathway GDF-3 is involved in. By inhibiting BMP type I receptors, Dorsomorphin prevents the phosphorylation and activation of SMAD proteins, thereby functionally inhibiting GDF-3 downstream signaling. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 acts as a selective BMP inhibitor which targets the BMP receptors. Inhibition of these receptors impairs the BMP signaling cascade, which GDF-3 is part of, thus resulting in the functional inhibition of GDF-3 activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 selectively inhibits the activin receptor-like kinases (ALK) which are integral to the TGF-beta signaling pathway, a pathway in which GDF-3 participates. Inhibiting this pathway functionally prevents GDF-3 from exerting its effects. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
DMH1 is a selective BMP receptor inhibitor which blocks BMP signaling. Since GDF-3 is a member of the TGF-beta superfamily and can engage in BMP signaling, DMH1 functionally inhibits GDF-3 by blocking its signaling pathway. | ||||||
K02288 | 1431985-92-0 | sc-488981 | 5 mg | $330.00 | ||
K02288 is another potent and selective inhibitor of the BMP type I receptors. By blocking these receptors, it functionally inhibits GDF-3 as it disrupts the BMP signaling pathway that GDF-3 utilizes to exert its biological functions. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117 inhibits BMP type I receptors ALK2 and ALK3, which are receptors that GDF-3 may engage with. By doing so, it functionally inhibits GDF-3 signaling, preventing its normal activity within the BMP pathway. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A 83-01 inhibits ALK5, ALK7, and TGF-beta type I receptors, which indirectly disrupts GDF-3 function since GDF-3 is part of the TGF-beta superfamily and relies on this pathway for signaling, leading to functional inhibition of GDF-3. | ||||||
LDN 193719 | 1062368-49-3 | sc-489383 | 10 mg | $189.00 | ||
LDN 193719 is a selective inhibitor of ALK1 and ALK2, which are part of the BMP receptor family. By inhibiting these receptors, ML347 can functionally inhibit the signaling pathways that GDF-3 uses, thus inhibiting GDF-3's activity. | ||||||
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline | 1432597-26-6 | sc-476318 | 5 mg | $380.00 | ||
LDN-212854 potently inhibits BMP receptor ALK2, which is involved in the BMP signaling pathway that GDF-3 participates in. This inhibition leads to a functional decrease in GDF-3 activity by blocking its ability to signal through this pathway. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
ALK5 Inhibitor II targets the TGF-beta type I receptor ALK5, which is involved in signaling pathways that GDF-3 uses. Inhibition of ALK5 would functionally inhibit GDF-3 by impeding its signaling capability within the TGF-beta pathway. | ||||||